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Abstract
Understanding the medical effect of an ever-growing number of human variants detected is
a long term challenge in genetic counseling. Functional assays, based on in vitro or in vivo
evaluations of the variant effects, provide essential information, but they require robust sta-
tistical validation, as well as adapted outputs, to be implemented in the clinical decision-
making process. Here, we assessed 25 pathogenic and 15 neutral missense variants of the
BRCA1 breast/ovarian cancer susceptibility gene in four BRCA1 functional assays. Next,
we developed a novel approach that refines the variant ranking in these functional assays.
Lastly, we developed a computational system that provides a probabilistic classification of
variants, adapted to clinical interpretation. Using this system, the best functional assay
exhibits a variant classification accuracy estimated at 93%. Additional theoretical simula-
tions highlight the benefit of this ready-to-use system in the classification of variants after
functional assessment, which should facilitate the consideration of functional evidences in
the decision-making process after genetic testing. Finally, we demonstrate the versatility of
the system with the classification of siRNAs tested for human cell growth inhibition in high
throughput screening.
Author Summary
Human genetics has entered a new age with the advent of next generation sequencing.
However, this great advance also comes with new concerns. Currently, the extensive use
of multi-gene panels, whole exome and whole genome sequencing, is generating an ever-
growing number of new DNA sequence variations detected in the disease-predisposing
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genes of human patients. The pathogenic or neutral status of these variants needs to be
known before planning any medical act or follow-up. We show here that the status of the
variants identified in the BRCA1 breast/ovarian cancer susceptibility gene can be esti-
mated thanks to experimental systems using yeast cells and a novel computational model.
Importantly, this model provides a probabilistic classification of variants, opening the pos-
sibility to integrate results from functional assays into clinical decision-making. Moreover,
our computational model is directly compatible with all kinds of experimental system
without any requirement for skills in statistics thanks to ready-to-use online tools. We
believe that this work is a step forward in the clinical interpretation of human genetic
variants.
Introduction
Genetic tests, that aim to identify disease-associated germline variants in the genome of patients
and relatives, have greatly expanded these last years, together with the number of predisposing
genes scrutinized [1]. Genetic tests are proposed by genetic counselors to identify the carriers of
genetic variants and to define appropriate clinical follow-ups and treatments for these carriers.
The detection of a variant can have severe psychological and physical consequences for the
tested patients, depending on whether the variant is known to be pathogenic (associated with
disease development), neutral (not related to disease development) or of unknown significance
(VUS). Thus, clinical decision-making after genetic testing requires the establishment of reliable
variant classifications. The best support is to use methods that attribute a probability of pathoge-
nicity for each variant identified. Because genetic/epidemiological methods, such as co-segrega-
tion, case-control, co-occurrence and familial data analyses, provide such probabilities [2], they
remain the gold standard in clinical decision-making after genetic testing (see an example in S1
Table). However, genetic/epidemiological methods are time consuming, as they require a sub-
stantial amount of observations. Moreover, they are unsuitable for a large number of variants
identified, for instance when the number of known carriers is rare. As genetic tests are evolving
towards the use of multi-gene panels, whole exome and whole genome sequencing [3], the num-
ber of VUS detected is inevitably increasing [1], which stresses the need to improve variant clas-
sification [3].
Functional assays have been designed to circumvent the limitations of genetic/epidemiologi-
cal methods. The generic "functional assay" term refers to in vitro and in vivo systems, able to
classify VUS by assessing their influence on protein function or conformation [4]. Functional
assays have been widely developed for genes involved in cancers [5] and BRCA1 has become
the leading gene analyzed, with 23 different assays proposed, to date [6]. However, despite the
genuine interest for strategies that alleviate the limitations of genetic/epidemiological methods,
the main challenge of functional assessment remains in its inclusion into clinical decision-mak-
ing. Indeed, most of the functional assays lack statistical validation [4]. Moreover, analyses are
usually based on visually defined cut-offs [6]. Finally, except in rare cases [7,8], the resulting
variant classifications lack the probability of pathogenicity provided by genetic/epidemiological
methods.
Here, we used experimental as well as computational approaches to overcome these limita-
tions. We evaluated the clinical utility of four different BRCA1 functional assays, designed in
yeast cells, by assessing 40 BRCA1missense mutations, previously classified by genetic/epide-
miological methods. To interpret these results, we developed a novel approach, referred to as
"Mann-Whitney-Wilcoxon (MWW) method", that defines a non-arbitrary best cut-off value
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making
PLOS Genetics | DOI:10.1371/journal.pgen.1006096 June 6, 2016 2 / 27
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
between the neutral and pathogenic variants and that refines variant ranking in data from func-
tional assays. We also developed a computational system that transforms the dual classification
between "pathogenic" or "neutral", provided by the non-arbitrary best cut-off, to a probabilistic
classification adapted to clinical decision-making. This system of classification, referred to as
"probability system", uses the fluctuation of the best cut-off to derive probabilities of pathoge-
nicity for each assessed variant. We show the benefit of our computational model, coupling the
MWWmethod and the probability system, using the experimental data from the four BRCA1
functional assays and using theoretical simulations. We also illustrate that our model is adapted
to experimental systems far beyond the genetic variant assessment, with the probabilistic classi-
fication of small interfering RNAs (siRNAs) tested for human cell growth inhibition in high
throughput screening.
Results
Forty missense mutations to evaluate the colony size assay
The colony size assay is a BRCA1 functional assay, that has been designed in the yeast model
organism, which allows rapid, large-scale and cost-effective variant assessment [9], but has
never been subjected to clinical validation yet. In this functional assay, expression of the full
length wild type (WT) BRCA1 protein in yeast, induces a growth defect [9–11]. Indeed, after
63 hours of growth on an agarose plate, a single yeast cell gives rise to a colony varying between
5,000 and 21,000 cells (Fig 1A, BRCA1), while colonies reach several millions of cells without
protein expression (Fig 1A, Vector control). To ascertain the utility of this assay in clinical
medicine, we selected 40 BRCA1 missense mutations, according to their neutral or pathogenic
classification by genetic/epidemiological methods (S1 Fig and S2 Table). We confirm that path-
ogenic missense mutations restore the proliferation rate of yeast cells [10,11]. Indeed, patho-
genic mutations have a global tendency to give rise to the biggest colonies, while colony sizes
arising from neutral mutations remain close to those of the WT BRCA1 reference (Fig 1A).
However, the Colony Size assay does not fully discriminate between pathogenic and neutral
mutants. Indeed, variant medians appeared to continuously decrease fromM1689R (highest
median) to V1804D (lowest median), without clear gap between the pathogenic and neutral
regions. Moreover, the neutral M1652T mutation is clearly within the pathogenic sector and
the pathogenic R1699Wmutation slightly overlaps the neutral region. In such situations, it is
critical to have a sound evaluation of the sensitivity, specificity and accuracy of the assay (see
the definitions in the S1 Text), which depends on a non-arbitrary and optimal cut-off setting.
The standard method to define the best cut-off
The standard method is based on the Youden's index, a classical approach to compute the sensi-
tivity and specificity in a dataset. Using this, the cut-off of 17,910 cells per colony gives the best
combined sensitivity and specificity, with 96% (24/25) and 93% (14/15) respectively (Table 1
and S2A Fig). In total, 95% (38/40) of the mutations are correctly classified. The M1652T neu-
tral mutation is misclassified as pathogenic and the pathogenic R1699Wmutation is misclassi-
fied as neutral (S3 Table). From now on, we refer to "experimental best cut-off", "experimental
sensitivity", "experimental specificity" and "experimental accuracy" as the best cut-off, sensitivity,
specificity and accuracy obtained from the experimental data.
The MWWmethod to define the best cut-off
The disadvantage of the standard method is that mutations are characterized by a single value,
here by the median of colony sizes, which can lead to paradoxes in the mutant classification.
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making
PLOS Genetics | DOI:10.1371/journal.pgen.1006096 June 6, 2016 3 / 27
Fig 1. Relative position of the variants in the Colony Size assay and fluctuation of the best cut-off. (A) Waterfall distribution
of colony sizes, according to median values (standard method). Boxplot representation results from 9 (mutants) or 36 (BRCA1 and
Vector) colony size values. The red and blue colors of the boxes indicate the pathogenic and neutral mutations, respectively,
according to their prior classification. Box central bar, median; box, interquartile range (50% of the distribution); whiskers, extreme
values; dotted horizontal line, median of BRCA1; thick horizontal line, experimental best cut-off (see S2 Fig). The distribution of the
best cut-off fluctuation, obtained after random sampling (bootstrap), of the 9 mutants and 36 BRCA1 values, is visualized by the
pink, grey and light blue areas, that delimit 4%, 90% and 4.9% of the distribution, respectively, which altogether represents a total
coverage of 98.9%. (B) Waterfall distribution according to p values (MWWmethod). The p value assigned to each variant is
symbolized by a segment. The upside-down representation facilitates the comparison of the mutation arrangement with the one
obtained in A. Arrows pinpoint a modification of the mutation rank depending on the method used. Framed mutations indicate
identical p values (see S4 Table). Segment colors, thick horizontal line and colored areas, as inA.
doi:10.1371/journal.pgen.1006096.g001
Table 1. Experimental sensitivity, specificity and accuracy of functional assays and siRNA screening using the experimental best cut-off.
Standard method MWW method
Assay Best
cut-off
Youden's
index
Sensitivity Speciﬁcity Accuracy Best cut-
off
Youden's
index
Sensitivity Speciﬁcity Accuracy
Colony Size 17 910 0.89 24/
25 = 0.96
14/
15 = 0.93
38/
40 = 0.95
0.009 0.89 24/
25 = 0.96
14/
15 = 0.93
38/
40 = 0.95
Liquid
Medium
0.172 0.81 22/
25 = 0.88
14/
15 = 0.93
36/
40 = 0.90
0.00023 0.80 20/
25 = 0.80
15/
15 = 1.00
35/
40 = 0.88
Spot
Formation
0.295 0.77 21/
25 = 0.84
14/
15 = 0.93
35/
40 = 0.88
0.165 0.77 21/
25 = 0.84
14/
15 = 0.93
35/
40 = 0.88
Yeast
Localization
0.057 0.69 19/
25 = 0.76
14/
15 = 0.93
33/
40 = 0.83
0.186 0.69 19/
25 = 0.76
14/
15 = 0.93
33/
40 = 0.83
siRNA 604 1.00 1/1 = 1.00 2/2 = 1.00 3/3 = 1.00 0.00044 1.00 1/1 = 1.00 2/2 = 1.00 3/3 = 1.00
"Accuracy" is the number of mutations or siRNA correctly classiﬁed. Sensitivities, speciﬁcities and accuracies, associated with the experimental best cut-
off, were referred to as "experimental", to distinguish them from those computed using the probability system of variant classiﬁcation.
doi:10.1371/journal.pgen.1006096.t001
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For instance, the neutral I1858L mutation displays a median of cells per colony higher than the
median of the neutral T1720A mutation. Thus, in the mutant ranking, I1858L is closer to the
pathogenic group of mutations than T1720A (arrows in Fig 1A). However, T1720A has three
values out of nine over the experimental best cut-off, which are thus in the pathogenic area,
while I1858L has none (S3A Fig). Therefore, in terms of dispersion range, T1720A could be
considered as "more pathogenic" than I1858L. To overcome such paradoxes in variant classifi-
cation, we developed a nonparametric approach to define the best non-arbitrary cut-off value,
that takes into account more information from distributions than the median value alone. This
method is based on the MWW test [12–14]. Since the p value of this test provides a quantifica-
tion of the overlap between two distributions (S4 Fig), we compared each mutant distribution
to the WT BRCA1 distribution. The p values obtained defined relative positions of the mutant
distributions using the WT BRCA1 distribution as a reference position (Fig 1B and S4 Table).
Contrary to the standard method described above, the cut-off used to compute the sensitivity
and specificity parameters is a p value. Any mutant with a p value below the p value cut-off,
indicates a mutant classified as pathogenic. In contrast, a mutant distribution with a p value
over the p value cut-off is considered as neutral. Strikingly, the MWWmethod solves the para-
doxes observed with the standard method, since T1720A is closer to the pathogenic group of
mutations than I1858L (arrows in Fig 1B). Moreover, the experimental sensitivity and specific-
ity remains unchanged (Table 1 and S2E Fig). This confirms that the M1652T and R1699W
mutations cannot be correctly classified by the Colony Size assay, even when using more infor-
mation from the experimental data than the variant medians alone. However, it also empha-
sizes that the variant classification, provided by the MWWmethod, does not diminish the high
sensitivity and specificity of the assay. From this, we conclude that the MWWmethod is a reli-
able alternative to the standard method to define a non-arbitrary cut-off in data from func-
tional assessments.
The probability system of classification
Recently, two-component models have been proposed for the probabilistic classification of var-
iants based on functional assessment. These parametric models require the normal distribution
of the neutral and pathogenic values [7,8]. However, as shown in S5A Fig, the Colony Size
assay is poorly compatible with such models, due to the bimodal distribution of the pathogenic
values. Therefore, we designed an alternative nonparametric and more versatile system of clas-
sification. This system is based on the fact that the best cut-off is a random variable that fluctu-
ates, depending on the experimental values. We asked what the variant classification would be,
using the Colony Size assay, taking this fluctuation into account. For this, we performed sam-
pling with replacement (bootstrap) of the colony size values, by randomly choosing 9 values
among the 9 from each mutant, and 36 values among the 36 from the BRCA1 reference con-
trol. Next, using this new set of sampled data, we applied the standard or MWWmethod to
obtain the best cut-off. We repeated this procedure a large number of times, which allowed us
to define a best cut-off distribution for the standard and MWWmethods (S5 Table). We also
used a third method, referred to as "standard with reference method". It is similar to the stan-
dard method, except that the best cut-off distribution obtained includes the fluctuation of the
WT BRCA1 reference, as explained in the S1 Text. Notably, the standard with reference
method allows an additional comparison with the MWWmethod, which also includes the fluc-
tuation of the WT BRCA1 reference. Finally, we designed the probability system of classifica-
tion. This system allows to assign a probability of pathogenicity to each assessed variant, using
the best cut-off fluctuation (Fig 2A and S6 Fig). The rationale is that the farther a variant is
from the core of the best cut-off fluctuation, the more robust is its classification as either
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Fig 2. Variant classification using the probability system. (A) Schematic of the probability system of classification. The left
figure depicts a theoretical waterfall distribution of pathogenic and neutral missensemutations, as in Fig 1B. Horizontal black line,
experimental best cut-off. (1) Variant classification according to the experimental best cut-off (method used in Table 1). (2)
Distribution of the best cut-off generated by bootstrap analysis from the experimental data. (3) Cumulative distribution function
(CDF) derived from the distribution of the best cut-off. This CDF provides a probabilistic classification of the variants, depending on
their positions in the CDF. (B) Classification of the BRCA1 variants assessed in four functional assays. Colored background in the
table indicates the five-class nomenclature, as in S1 Table. Names in red and blue indicate the pathogenic and neutral mutations,
respectively, according to their prior classification. The sensitivity, specificity and accuracy computation are detailed in S6 Table.
doi:10.1371/journal.pgen.1006096.g002
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pathogenic or neutral. A probability close to 1 indicates that the variant can be classified as
pathogenic, with a low risk of misclassification as neutral due to the fluctuation of the best cut-
off. A probability close to 0 indicates that the variant can be classified as neutral, with a low
risk of misclassification as pathogenic due to the fluctuation of the best cut-off. Finally, a prob-
ability of 0.5 designates no preferential classification as either neutral or pathogenic (variant
completely unknown). With such probabilities, the five-class nomenclature proposed by Plon
et al [26]. (S1 Table) can be directly applied to functional assays. Probabilities obtained for the
Colony Size assay are shown in Fig 2B. Strikingly, a level of uncertainty was generated, notably
with variants classified as "uncertain" (class 3). This highlights the critical influence of the best
cut-off fluctuation in variant classification. In addition, the MWWmethod exhibits the best
accuracy, with 37/40 mutations correctly classified versus 36/40 for the standard and standard
with reference methods. When including the number of misclassified mutations, the MWW
method shows a balance of 35 mutations, ex-aequo with the two other methods (S6 Table).
Altogether, these results confirm the possibility to use the MWWmethod in variant classifica-
tion. In addition, the probability system seems to be an effective and simple way to obtain a
probabilistic classification of variants in functional assessment.
Evaluation of three additional functional assays
We validated three other functional assays, by assessing the same 40 mutations used in the Col-
ony Size assay. The Liquid Medium assay monitors the growth defect of yeast cells expressing
BRCA1 (S7 and S8 Figs), as in the Colony Size assay, but in liquid instead of solid medium
[11]. The Spot Formation assay is derived from the observation that the BRCA1-mCherry
fusion protein accumulates in a single aggregate in the nucleus of yeast cells. This aggregate is
referred to as "spot" due to its visual signature using fluorescent microscopy. We previously
showed that pathogenic missense mutations decrease the proportion of cells showing one spot
[11]. Here, we confirmed this effect (S9 and S10 Figs). The last assay tested was the Yeast Local-
ization assay. Whereas cytoplasmic spots are rare in yeast cells expressing the WT BRCA1 pro-
tein, this event has a tendency to increase in the presence of pathogenic mutations [11]. Here,
we confirmed this effect (S11 and S12 Figs). However, albeit promising, none of these three
assays provided a better discrimination than the Colony Size assay, to distinguish between
pathogenic and neutral variants. This was notably shown by the experimental sensitivity and
specificity computed (Table 1 and S3 Table).
The classification model challenged by the four functional assays
We took advantage of the experimental differences among the four assays (recapitulated in S7
Table) to detect potential flaws in the MWWmethod. In contrast, the MWWmethod con-
stantly overcomes the incoherent ranking generated by the standard method (see examples in
S7, S9 and S11 Figs). This is achieved without reducing the experimental accuracy compared to
the standard method (Table 1), except for a minor decrease in the Liquid Medium assay (88%
versus 90%). Also, no flaws were detected in the probability system, which would result in an
unexpected high level of misclassifications (Fig 2B). Interestingly, accuracy of the MWW
method is globally better than in the standard or standard with reference method, with the best
accuracy of 93% in the Colony Size assay, 83% in the Spot formation assay, and with the best
ex-aequo accuracy of 73% in the Yeast Localization assay (Fig 2B). Variant misclassification
was slightly higher in the MWWmethod, compared to the two other methods, with one more
misclassification in the Colony Size and in the Spot Formation assays, one less in the Liquid
Medium assay, and ex-aequo in the Yeast Localization assay ("Total number of variants mis-
classified" column in S6 Table), even if the balance between accuracy and misclassification
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maintains the MWWmethod as the best one, ex-aequo with the standard method ("Balance"
column in S6 Table). Finally, contrary to the MWWmethod, the standard method suffers from
a lack of sensitivity in the Yeast Localization assay, since none of the pathogenic mutations are
classified as class 5 (Fig 2B). Overall, the analysis of four functional assays did not reveal any
major flaw in the probability system of classification. In addition, the results obtained with the
MWWmethod confirm the possibility to classify variants using more information from the
variant distribution than the median value alone.
The classification model in theoretical simulations
To complete the detection of potential flaws in our classification model, we analyzed theoretical
situations. A reference situation was designed, similar to that in the Colony Size assay (S8
Table). Next, different parameters were scrutinized: the position of the pathogenic mutations
(S13 Fig), neutral mutations (S14 Fig), or WT BRCA1 reference (S15 Fig), the initial sensitivity
and specificity of the assay before using the probability system (S16 Fig), the number of neutral
and pathogenic variants used (S17 Fig), the number of values in the variants and in the WT ref-
erence distributions (S18 Fig), and the range of the variant and WT reference distributions
(S19 Fig). Results are recapitulated in S9 Table and summarized in Table 2. The standard with
reference method shows strong usage limitations, notably when the WT reference exhibits a
negative median or a median close to zero (Table 2 and S15E Fig, middle panel). Interestingly,
the MWWmethod is not affected by such situations. The main limitation detected is an
extreme situation in which the WT reference distribution falls outside of the range of the neu-
tral and pathogenic distributions (e.g., S15A Fig, left panel), which impairs the sensitivity of the
probability system of classification (Table 2 and S15E Fig, right panel). Except for this extreme
situation, we confirm the efficient behavior of our classification model, coupling the MWW
method and the probability system: (1) when the pathogenic and neutral distributions are
Table 2. Usage limits of the probability system of classification.
Method Limits Figure
All of them - Weak experimental speciﬁcity S16
- Weak experimental sensitivity S16
- Low number of values in the data set S18
- No dispersion in both the WT reference and the mutant distributions S19
Standard - Close neutral and pathogenic medians S13,
S14
Standard with
reference
- Close neutral and pathogenic medians S13,
S14
- WT reference median close to zero and ﬂuctuation of the raw best cut-
off far from this median
S15
- WT reference with a negative median S15
MWW - Close neutral, pathogenic and WT reference distributions S13,
S14
- WT reference distribution outside of the range of the neutral and
pathogenic distributions
S15
This table recapitulates the results obtained with the three standard, standard with reference and MWW
methods, when challenged by theoretical distributions. Usage limits were deﬁned as situations in which the
neutral and pathogenic mutations, used to generate the ﬂuctuation of the best cut-off, are ﬁnally not
classiﬁed as class 1/2 and 4/5, respectively (neutral mutations ﬁnally classiﬁed as class 3, 4 or 5, and
pathogenic mutations ﬁnally classiﬁed as class 3, 2 or 1).
doi:10.1371/journal.pgen.1006096.t002
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strictly identical, all the mutations are classified as class 3 (Table 2 and S13D Fig, right panel),
(2) the sensitivity and specificity of the probability system of classification increase when path-
ogenic mutations move away from the WT BRCA1 reference distribution (S13D Fig, right
panel), and (3) when pathogenic mutations are contaminated by neutral mutations (experi-
mental specificity reduced), the sensitivity of the probability system of classification is
decreased (Table 2 and S16E–S16G Fig, right panel), and vice versa. This last result is an
important criterion for classification, since unknown mutants that would be located in a patho-
genic region containing neutral mutations, could not be formally classified as pathogenic.
Therefore, it is noteworthy that the experimental sensitivity and specificity values are taken
into account by our classification model. Interestingly, the model is poorly sensitive to the
number of neutral or pathogenic mutations used to validate a given assay (S17E–S17G Fig,
right panel), as long as the number of values in the dataset is high enough (S18E–S18G Fig,
right panel). Supplemental information is provided in the S1 Text. This notably includes an
extensive analysis of the best cut-off fluctuation, which explains the lack of sensitivity of the
standard method, mentioned above in the Yeast localization assay (Fig 2B) and also shown in
theoretical situations (see the legend of S13 Fig). It also contains specific procedures for variant
classification (e.g., Bayesian inference, combination of functional results, assessment of VUS),
as well as procedures to fit the proposed model to other situations. It finally includes the Pro-
Class toolbox that generates the probabilistic classification of variants, adapted to most kind of
functional assays.
The classification model in high throughput screening
We wondered if the classification model developed for genetic variants could be easily extended
to other decision-making situations. The analysis of theoretical situations showed that variant
classification remains accurate when only one neutral and one pathogenic variant are available
(S17E–S17G Fig). This indicates that the fluctuation of the best cut-off supports decision-mak-
ing in situations represented by a limited number of positive and negative controls. To confirm
this, we analyzed data from 406 genes targeted by small interfering RNAs (siRNAs), screened
for their capability to inhibit the proliferation of a human prostate tumoral cell line (Fig 3).
The "No siRNA" control, the siKIF11 positive control and the siGOLGA2 and siGL2 negative
controls were treated as WT reference, pathogenic and neutral variants, respectively. Structure
of the data is reported in S7 Table. As in the BRCA1 functional assays, the experimental accu-
racy was not impaired using the MWWmethod, compared to the standard method (Table 1).
In addition, no flaws were detected in the probability system, since the accuracy remained at 1,
whatever the standard, standard with reference or MWWmethod used (Fig 3C). Finally, the
advantage of the MWWmethod is again highlighted in the final classification of the screened
siRNAs. Indeed, in the siRNA ranking, based on the median values, siGTSE1 is closer to the
negative controls than siITGA2 (Fig 3A). By taking the distribution of these two siRNAs into
account, the MWWmethod switches their ranking position (Fig 3B), so that siGTSE1 is finally
classified as "unclear effect on cell growth inhibition" (Fig 3C, MWWmethod), instead of "no
cell growth inhibition" (Fig 3C, standard and standard with reference methods). Thus, this
demonstrates that our probabilistic model is also adapted to the classification of experimental
data far beyond the functional assessment of genetic variants.
Discussion
We provide the statistical validation of four BRCA1 functional assays, as well as a classification
model that facilitates the incorporation of functional assay results into clinical decision-mak-
ing. The probabilistic model is based on the fluctuation of the best cut-off, which is driven by
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the fluctuation of the experimental data. Thus, the variant classification provided reflects the
robustness of a cut-off-based decision-making towards data fluctuation. The model has the
advantage to be nonparametric, easy to handle and easy to adapt to most kind of functional
assays. Moreover, among the variants incorporated in functional assays, the model only
depends on those previously classified by genetic/epidemiological methods as pathogenic or
neutral. It is not influenced by unknown variants, meaning that the subsequent incorporation
of unknown variants in a functional assay does not require a new analysis of the best cut-off
fluctuation. These features of our model contrast with parametric models, proposed for variant
classification [7,8].
We achieved a widespread analysis of the best cut-off fluctuation dedicated to decision-
making (completed in the S1 Text). This analysis is focused on the classification of genetic vari-
ants, but it is also valid for other decision-making situations compatible with our classification
model, such as high throughput siRNA screenings. Using many different kinds of data struc-
tures (four BRCA1 functional assays, one siRNA screen and 93 theoretical situations), three
different methods of best cut-off fluctuation were scrutinized: the standard, the standard with
reference and the MWWmethods. From this study, we conclude that the standard with refer-
ence method is poorly compatible with a versatile classification model, due to important lacks
of accuracy when the WT reference exhibits a negative median or a median close to zero (S15E
Fig, middle panel). The standard method has the advantage to support decision-making in
Fig 3. High throughput siRNA screening and fluctuation of the best cut-off. An average of 150 human
prostate tumoral cells were plated, treated with siRNAs targeting the indicated gene and grown for 72 hours
before cell counting. TheWT reference (No siRNA), the positive control of cell growth inhibition (siKIF11), the
two negative controls of cell growth inhibition (siGOLGA2 and siGL2) and 8 among 406 siRNA targeted genes
are shown. The complete analysis of the 406 targeted genes is available using the ProClass toolbox and the
included siRNA full.txt file, as explained at the end of the README.doc file. (A) Waterfall distribution of cell
growth after siRNA treatment, according to median values (standard method). As in Fig 1A, except that boxplot
representation results from 12 (siRNA) or 1,140 (No siRNA) values. (B) Waterfall distribution according to p
values (MWWmethod), as in Fig 1B. (C) Classification of the siRNA targeted genes, as in Fig 2B, except that
probabilities are related to cell growth inhibition, with the corresponding five-class nomenclature: "no inhibition"
(blue, class1), "likely no inhibition" (light blue, class2), "unclear inhibition" (grey, class3), "likely inhibition" (light
red, class4) and "inhibition" (red, class5).
doi:10.1371/journal.pgen.1006096.g003
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experimental situations devoid of a WT reference. The MWWmethod has the advantage to
use more information from the distribution of the classified elements than the median value
alone. This refines the ranking and the final probabilistic classification. Contrary to the stan-
dard method, the MWWmethod is adapted to experimental situations in which the neutral
and pathogenic variants (or the negatives and positives controls) are represented by a single
value if the WT reference encompasses a significant number of different values (S18E Fig, com-
pare the left and right panels for the mutant with one value). However, the MWWmethod is
poorly adapted to experimental situations where the WT reference distribution is more or less
outside of the range of the neutral and pathogenic distributions (e.g., S15A Fig, left panel).
Thus, we propose to prioritize the MWWmethod if the data are compatible with this method,
notably if the WT reference is well embedded in the neutral/negative distributions, or if the
WT reference is between the neutral/negative and the pathogenic/positive distributions, and
to use the standard method otherwise. The different methods are proposed in the ProClass
toolbox available online (see the S1 Text).
Interestingly, none of the four yeast assays is able to correctly classify the R1699W patho-
genic and the K45Q neutral variants. Pathogenicity of R1699W has been long-established in
independent studies, using different genetic/epidemiological methods [15–17], confirming that
yeast cells are unable to detect the deleterious impact of R1699W [18]. This emphasizes that
the mechanism of R1699W, leading to tumor development, is different from the other patho-
genic missense variants of BRCA1. It is probably related to a protein-binding defect without
major BRCA1 structural destabilization [19]. The classification of K45Q has been established
by a single epidemiological study [20], with little evidences of neutrality (e.g., probability of
being pathogenic of 11% by family history prediction). However, the absence of any functional
impact has been confirmed in three different functional assays using mammalian cells [21,22],
which stresses a specific effect of K45Q in yeast cells, that remains to be explained.
Finally, this work showed that the yeast organism can be used to classify variants positioned
in both Nter and Cter parts of BRCA1. Among the four assays analyzed, the Colony Size assay
is the most accurate (93%) and the most robust to data fluctuation (one class 3 variant). The
Liquid Medium and Yeast Localization assays may also be attractive for diagnosis due to the
absence of false negative results detected, notably when using the MWWmethod. Interestingly,
the Yeast Localization assay allows the identification of pathogenic variants that delocalize the
BRCA1 protein into the cytoplasm. If confirmed in human cells, this assay could define subcat-
egories in the pathogenic variants of BRCA1, based on different cellular mechanisms leading to
tumor development.
Methods
Plasmids
All plasmids are derived from pJL48 [11], a modified version of pESC-URA (Agilent Technolo-
gies), in which theMYC epitope has been removed by SalI-XhoI digestion and vector ligation.
In this plasmid expression of the cDNA is controlled by the GAL1 promoter, inducible by
galactose and repressed by glucose. The backbone of the human BRCA1 (MIM# 113705)
cDNA used, corresponds to the AY888184.1 GenBank sequence with a TGA stop codon
instead of TAG. To facilitate the cloning of BRCA1 missense mutations, silent mutations were
inserted in the cDNA to generate 4 new restriction sites: SalI (c.1020A>C + c.1023T>C),
AvrII (c.4662A>T), FseI (c.4839T>G + c.4842A>G + c.4845T>C) and XhoI (c.5502C>T).
Of note, the WT BRCA1 and BRCA1-mCherry plasmids used in this study (pPT60 and pPT63
respectively, see S10 Table) are different from the pJL45 and pGM40 plasmids, used in our pre-
vious publication [11], by the addition of the 4 restriction sites. The 40 missense mutations
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were generated by targeted mutagenesis (Genscript Company, Piscataway, NJ, USA) on inter-
mediate plasmids. Next, we inserted the mutated cDNA fragment into the pPT60 and pPT63
plasmids by a single digestion—ligation step. All resulting plasmid constructs were verified by
sequencing the promoter, the full cDNA and the terminator.
Yeast strains
Transformation of the Saccharomyces cerevisiae haploid BY4741 or YKR082W-GFP strains
were performed as previously described [11]. The strains generated are referenced in S11
Table. To facilitate the description, we referred to the cells transformed with pESC-URA as the
name of the cDNA inserted into the plasmid. Thus, "BRCA1" refers to yeast cells transformed
with the plasmid containing the WT BRCA1 cDNA; "M18T" refers to yeast cells transformed
with the plasmid containing the M18T mutated version of the BRCA1 cDNA; and "vector"
refers to yeast cells transformed with the same plasmid without inserted cDNA. Three indepen-
dent transformants per strain, also referred to as "clones", were selected after each transforma-
tion. We observed that lithium acetate transformation can result in diploidisation of haploid
cells. To control this, the ploidy of each clone was verified by FACS analysis, using the yeast
strain BY4741 (haploid) and BY4743 (diploid) as a control. Next, in the different assays, cells
were grown in glycerol-lactate medium (GL-URA) as previously described [11]. Addition of
galactose in the medium (GAL) induced the expression of BRCA1, while addition of glucose
(GLU) strongly repressed the expression of BRCA1.
Fluorescence-activated cell sorting (FACS) analysis
Cells were grown in log phase in YPD medium (1% yeast extract, 2% peptone, 2% dextrose,
60 μMAdenine, 8 μMNaOH). 107 cells were collected and put at 4°C to block the cell cycle.
Cells were centrifuged at 4°C and resuspended in 70% ethanol. After 1 hour incubation at
room temperature (RT), cells were centrifuged and resuspended in freshly made sodium citrate
[50 mM] pH7. Sonication was performed to dissociate cell aggregates (Vibracell and probe
CV33 (Bioblock Scientific, Illkirch, France), pulse 30%, time 15 seconds). Cells were centri-
fuged and resuspended in sodium citrate [50 mM] pH7 + RNAse A [0.25 mg/ml]. After 1 hour
incubation at 50°C, cells were centrifuged, resuspended in sodium citrate [50 mM] pH7 + Pro-
pidium Iodide [16 μg/ml] and analyzed using an Accuri (BD Bioscience, San Jose, CA, USA).
Colony size assay
This assay was previously named "small colony phenotype" (SCP) assay. The method already
published [11] was slightly improved as follows: (1) GL-URA+galactose and GL-URA+glucose
plates were incubated 63 hours and 50 hours respectively (instead of 52 hours), and (2) the big-
gest colony of each plate, representing the size of at least five other colonies on the plate, was
chosen for cell counting. This prevents the choice of rare but extremely big colonies (outliers).
For the simultaneous assessment of 10 variants by a single technician, the time required
between the delivery of the intermediate plasmids (see above) and the final results is 20 days.
Liquid medium assay
This method already published [11] was slightly improved as follows: during glucose induction,
cells were diluted at 0.5×106 cells/ml (instead of 106 cells/ml) for the 15 hour culture time at
30°C. Galactose induction conditions remained as before. For the simultaneous assessment of
10 variants by a single technician, the time required between the delivery of the intermediate
plasmids (see above) and the final results is 20 days.
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Spot formation and yeast localization assays
This method already described [11] was slightly improved as follows. Briefly, Nup133-GFP
cells, expressing theWT or mutated BRCA1 protein fused to mCherry, were induced for 4
hours with galactose before analysis using live fluorescent microscopy. The previously named
"yeast localization phenotype" (YLP) assay [11] was subdivided into two assays in this study.
The Spot Formation assay monitors the proportion of cells showing a single aggregate of WT or
mutated BRCA1, visible in fluorescent microscopy, without considering the intracellular locali-
zation. This aggregate is also referred to as "spot". Cells with several aggregates were not consid-
ered in this assay. The Yeast Localization assay monitors the proportion of spot volumes
localized in the cytoplasm of yeast cells. Picture acquisitions were previously described [11]. For
each clone, at least three fields, containing at least 100 cells, were acquired. For the Spot Forma-
tion assay, the number of cells showing one spot was manually counted. Next, the proportion of
cells containing one spot was computed by dividing the number of cells showing one spot to the
total number of cells (one value per clone). For the Yeast Localization assay, images of the three
fields were deconvoluted [23] and the volume Volij of each spot i, in the field j, was measured
using the 3D Object Counter plugin [24] of ImageJ. Next, each spot was manually categorized as
"inside" or "outside" the nucleus. Finally, the proportion of volume outside the nucleus was com-
puted using the formula (SiSjVolij/outside) / (SiSjVolij/outside + SiSjVolij/inside), which led to one
value per each clone assessed. This proportion quantifies the cytoplasmic localization of the
mCherry protein fused to BRCA1. For the simultaneous assessment of 10 variants by a single
technician, using the Spot Formation and Yeast Localization assays, the time required between
the delivery of the intermediate plasmids (see above) and the final results is 21 days.
High throughput siRNA screening
IGR-CaP1 epithelial cells, derived from a human prostate primary tumor [25], were plated in
384-well plates at 750 cells/well, were allowed to adhere overnight and then were transfected
with a single siRNA from a siRNA library targeting 406 different genes. siKIF11, siGL2 and
siGOLGA2 were used as controls. After 72 hours, cells were fixed and nuclei were stained with
DAPI. Images were acquired with an INCell 2000 automated wide-field system (GE Health-
care, Little Chalfont, UK) and cell counts were quantified in each well with the INCell Analyzer
workstation software (GE Healthcare). The pictures analyzed represent 20% of the well surface,
which corresponds to an average of 150 cells initially plated for this surface.
Statistical and computational methods
Statistical and computational methods, as well as R source codes, are provided in the S1 Text.
Supporting Information
S1 Supporting Information. Joined Supplementary Methods, Figures and Tables.
(PDF)
S1 Text. Supplementary Methods.
(PDF)
S1 Fig. Position of the BRCA1 missense mutations selected. RING domain (amino acid
8–96); BRCT, BRCA1 C-terminal domains (amino acid 1646–1736 and 1760–1855). Patho-
genic and neutral mutations are in red and blue, respectively. Fourteen mutations (3 neutral
and 11 pathogenic) map within the RING domain. An additional neutral mutation, N132K,
flanks the Cter part of this domain, resulting in 15 mutations located in the Nter extremity of
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BRCA1. Twenty-five mutations (11 neutral and 14 pathogenic) lie in the BRCT domain, at the
Cter extremity of the protein. Of note, the RING domain suffers from a lack of neutral mis-
sense mutations classified by genetic/epidemiological methods, explaining why only 3 neutral
mutations from our selected panel, lie in this domain. Moreover, no pathogenic missense
mutations, between the amino acids 65 and 1684, are documented in the BRCA1 mutation
databases (S2 Table). Therefore, this study was restricted to the RING and BRCT domains of
BRCA1.
(PDF)
S2 Fig. Experimental best cut-off, experimental sensitivity and experimental specificity of
functional assays. (A-D) Standard method. The medians of the mutant distributions were
ordered (as in the waterfall distribution, Fig 1A) and each average position between two conse-
cutive medians was defined as a cut-off. For example, in Fig 1A, the cut-off between the two
first mutations, M1689R and V1838E, was (1,877,333 + 1,621,333) / 2 = 1,749,333 cells per col-
ony. Next, sensitivity was defined as the proportion of pathogenic mutant medians above (for
the Colony Size, Liquid Medium and Yeast Localization assays) or below (for the Spot Forma-
tion assay) a selected cut-off. The associated specificity was defined as the proportion of neutral
mutant medians below (Colony Size, Liquid Medium and Yeast Localization assays) or above
(Spot Formation assay) the same selected cut-off. For example, for the cut-off between
M1689R and V1838E in Fig 1A, the sensitivity was 1/25 = 4% and the specificity was 15/
15 = 100%. Sensitivity and specificity were computed for each cut-off (left panels). Areas sur-
rounding the curves delimit the 95% confidence interval according to the binomial law. The
ROC curve (right panel) pinpoints the best cut-off (black number), meaning the cut-off that
maximizes both sensitivity and specificity of the assay. Precisely, the best cut-off is the one
associated with the highest vertical distance of the ROC curve to the dotted diagonal. This
highest vertical distance is referred to as "Youden's index", which is equal to max[sensitivity
+ specificity—1]. In other words, the best cut-off is the cut-off of the Youden's index. Other
cut-off values are also positioned on the ROC curve (grey numbers). Blue, red and orange dots
on the curves of the left and right panels represent the different cut-offs tested. The black verti-
cal bar, in the left panel, pinpoints the best cut-off defined on the ROC curve. (E-H) MWW
method. As in A-D for mutant p values, instead of mutant medians. In all assays, sensitivity
was defined as the proportion of pathogenic mutant p values below a selected cut-off, and the
associated specificity was defined as the proportion of neutral mutant p values above the same
selected cut-off. (A, E) Colony Size assay. (B, F) Liquid Medium assay. (C, G) Spot Formation
assay. (D,H) Yeast Localization assay.
(PDF)
S3 Fig. Supplemental information in the colony size assay. (A) Dotplot distribution of col-
ony sizes. For each missense variant, the nine represented values result from three independent
clones examined in three independent experiments. For the BRCA1 reference and the Vector
control, the 36 values result from three independent clones examined in twelve independent
experiments (represented in the three panels, except for the Vector values absent in the top
panel). Grey bar, median; dotted horizontal line, median of BRCA1; black horizontal line,
experimental best cut-off. The top panel (Nter extremity of BRCA1) has a y-axis scale magni-
fied compared to the middle and bottom panels (Cter extremity of BRCA1). (B) As in A with
glucose instead of galactose media (see the S1 Text) to verify that each clone had no intrinsic
growth defect, independent of WT or mutated BRCA1 expression. The three independent
clones from A were examined in one experiment.
(PDF)
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making
PLOS Genetics | DOI:10.1371/journal.pgen.1006096 June 6, 2016 14 / 27
S4 Fig. The MWWmethod. (A) Upper-sided MWW test. The theoretical examples are based
on the Colony Size assay but are also valid for the Liquid Medium and Yeast Localization
assays. Each distribution of the WT BRCA1 reference (black) and the missense mutation (pur-
ple) are composed of 8 theoretical values, represented by 8 dots in the diagram. The p value of
the MWW test is used to score the overlap of the mutant and the WT BRCA1 distributions.
See the S1 Text for full details. From left to right: (1) when all the mutant values are below the
BRCA1 values, the upper-sided MWW test results in a p value close to 1; (2) the p value
decreases when the mutant distribution begins to overlap the BRCA1 distribution; (3) the p
value is approximately 0.5 when the two distributions completely overlap; (4) the p value con-
tinues to decrease when the mutant distribution is above the BRCA1 distribution, with a partial
overlap; (5) finally, the p value is lowest when the mutant distribution is fully above the BRCA1
distribution. In theory, neutral and pathogenic mutations should have a p value close to 0.5
and 0, respectively, as depicted by the color scale below the diagram. However, the absolute p
value attributed to each variant is not determinant. What is significant is the relative positions
between the mutant distributions, indicated by the p values, using the WT BRCA1 distribution
as a reference position. The lowest p values represent systematically the pathogenic mutations,
and the highest the neutral mutations. Thus, the upper-sided MWW test is used when patho-
genic mutations are above the neutral ones in the experimental data. (B) Lower-sided MWW
test. All of the theoretical examples shown are based on the Spot Formation assay. As in the
upper-sided MWW test, the lowest and highest p values still represent the pathogenic and neu-
tral mutations, respectively, but the pathogenic mutations are below the neutral ones in the
experimental data.
(PDF)
S5 Fig. Distribution of the pathogenic and neutral values. (A) Colony Size assay. The left
panel exhibits dotplot distributions. Boxplots provide distribution parameters: box central bar,
median; box, interquartile range (50% of the distribution); whiskers, extreme values. The mid-
dle panel shows the normal Quantile-Quantile (QQ) plot of the pathogenic values. Dots form-
ing a straight line suggest that the values are normally distributed. Black line, straight line
through the quantiles 25% and 75%. The right panel shows the normal QQ plot of the neutral
values. (B) Liquid Medium assay. (C) Spot Formation assay. (D) Yeast Localization assay.
(PDF)
S6 Fig. Description of the probability system of classification. (A) As in Fig 2A. (B) Theoret-
ical example showing how the values from the best cut-off fluctuation, derived from the MWW
method, are converted into probabilities of pathogenicity. Top table: best cut-off distribution
composed of 10 best cut-off values, resulting from 10 bootstraps (nbootstrap = 10). The probabil-
ity attributed to each best cut-off value was 1 / nbootstrap. Bottom table: cumulative distribution
functions (CDF) generated from the best cut-off distribution. In this table, probabilities of each
repeated cut-off value were summed. For instance, the best cut-off value of 0.9 is repeated 4
times in the top table, leading to a probability of 0.4. The CDF represents the sum of the proba-
bilities present in the second row of the bottom table. Three CDF were computed. The first
reaches the cumulated probability of 1. The second begins with the cumulated probability of 0.
The third is the average of the two first CDF. This average CDF delivers the probability of path-
ogenicity used to classify variants. Right panel: plot of the average CDF. To classify a variant
(e.g., M18T), the variant p value, derived from the MWWmethod, is positioned on the x-axis
(vertical grey bar). Next, the closest average CDF value is attributed to the variant as a probabil-
ity of pathogenicity. In this example, the best cut-off value, closest to M18T, is 0.5. Thus, the
corresponding probability 0.75 is attributed to M18T. (C-E) Average CDF of the Colony Size
(CS), Liquid Medium (LM), Spot Formation (SF) and Yeast Localization (YL) assays, obtained
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with the standard (C), standard with reference (D) or MWWmethod (E). The same procedure,
described in B, was applied to the 2,000 best cut off values obtained for each assay and each
method used. The CDF is ascending when the pathogenic mutations are above the neutral
ones, and descending when the pathogenic mutations are below. The number of different best
cut-off values is indicated (n = 2,000 when no identical best cut-off values within distribu-
tions).
(PDF)
S7 Fig. Relative position of the variants in the Liquid Medium assay and fluctuation of the
best cut-off. (A-B) As in Fig 1. One OD unit corresponds to 108 cells / ml. Arrows pinpoint the
ranking of the L22S and C47G mutations, which is improved using the MWWmethod, as
explained in the main text introducing this method. The incoherent ranking observed with the
standard method results from L22S that exhibits four values below the experimental best cut-
off while C47G has none (S8A Fig).
(PDF)
S8 Fig. Supplemental information in the liquid medium assay. (A-B) Same as for the Colony
Size assay (S3 Fig). One OD unit corresponds to 108 cells / ml.
(PDF)
S9 Fig. Relative position of the variants in the Spot Formation assay and fluctuation of the
best cut-off. (A-B) As in Fig 1, except that boxplots and p values resulted from 3 (mutants) or
12 (BRCA1) values. Arrows pinpoint the ranking of the M18T and C39Y mutations, which is
improved using the MWWmethod, as explained in the main text introducing this method.
The incoherent ranking observed with the standard method results fromM18T that exhibits
one value above the experimental best cut-off (shown by the top whisker overlaying the thick
horizontal line) while C39Y has none.
(PDF)
S10 Fig. Supplemental information in the Spot Formation assay.Nup133-GFP cells, express-
ing theWT or mutated BRCA1 protein, fused to mCherry, were analyzed using live fluorescent
microscopy. (A) Examples of images acquired. Nup133-GFP allows visualization of the nuclear
membrane within the cell, in the green channel. Overlayed images of GFP and mCherry
(Merge) as well as transillumination images (Trans) are also shown. Scale bar, 5 μm. (B) Image
quantifications. Bars and whiskers indicate median and extreme values for each distribution,
respectively. For each assessed clone, the total number of cells showing one spot, two spots,
more than two spots, or a diffusive signal, was counted. Three clones were assessed once, for
each missense mutation, and 4 times for theWT BRCA1 reference. Thus, each bar in the dia-
gram is the result of 3 values, for each missense mutation, and 12 values for theWT BRCA1
reference. In the Spot Formation assay, only the "1 spot" category is considered. The dotted
horizontal line represents the median of BRCA1. (C) Dotplot representation of the 12 BRCA1
values. The equivalent dotplot distribution of each mutant is shown in B, with the 3 values
from each mutant represented by the top of the dark grey bar and the two whisker extremities,
and also in S9A Fig, where the 3 values correspond to the median bar and the two whisker
extremities.
(PDF)
S11 Fig. Relative position of the variants in the Yeast Localization assay and fluctuation of
the best cut-off. (A-B) As in Fig 1, except that the boxplots and p values are the results of 3
(mutants) or 12 (BRCA1) values. Delocalization of the mCherry fluorescent signal from the
nucleus ranges from 0 (no cytoplasmic delocalization) to 1 (full cytoplasmic delocalization).
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Arrows pinpoint the ranking of the A1669S and D67Y mutations, which is improved using the
MWWmethod, as explained in the main text introducing this method. The incoherent ranking
observed with the standard method results from A1669S that exhibits one value above the
experimental best cut-off while D67Y has none. (C) Dotplot representation of the 12 BRCA1
values forming the BRCA1 boxplot in A. The equivalent dotplot distribution of each mutant is
shown in A, with the 3 values from each mutant represented by the median bar and the two
whisker extremities.
(PDF)
S12 Fig. Supplemental information in the yeast localization assay. Fluorescent images
acquired in the Yeast Localization assay, as in S10A Fig. The arrow points to rare cytoplasmic
spot in cells expressing the WT BRCA1-mCherry protein. Scale bar, 2 μm.
(PDF)
S13 Fig. Effect of the position of the pathogenic mutations on the probability system of
classification (theoretical situation). The parameters of the theoretical distributions used are
detailed in S8 Table. The reference situation is as follows: nmutant = 9, nBRCA1 = 36, nneutral = 15
and npathogenic = 25. In addition, medians and ranges of the neutral and WT BRCA1 distribu-
tions were made systematically equal. Distributions of the neutral and pathogenic mutations
were identical, except for the shift of the pathogenic values from the neutral mutations, accord-
ing to the formula vij + 36 × s, with s representing the shift intensity and vij representing the
value i of the pathogenic mutation j. When s = 0, pathogenic and neutral distributions are iden-
tical. Fluctuations from the best cut-off were obtained exactly as performed for the Colony
Size, Liquid Medium, Spot Formation and Yeast Localization assays. (A-C) Examples of shift
intensities and best cut-off fluctuation results. The graphs depicted are similar to those in Fig 1,
except that the standard, standard with reference and MWWmethods are shown respectively
on the left, middle and right of the figure. In the standard and standard with reference meth-
ods, boxplots are replaced by dotplots with the median of the distributions indicated by a grey
segment. The s values are indicated (top left). In the subsequent supplemental figures, the posi-
tion of the pathogenic mutation medians are as in C (s = 2). The grey horizontal line indicates
the median of the best cut-off fluctuation. (D) Probabilities of pathogenicity obtained for the
neutral (blue line) and pathogenic variants (red line), depending on the shift intensity of the
pathogenic mutations. Y-axis, log10(p / (1—p)) with p being the probability of pathogenicity
of the variants (0 corresponds to p = 0.5); right colored classes, five-class nomenclature with
the horizontal grey lines showing the 0.99, 0.95, 0.05 and 0.001 limits of the classes (see S1
Table). In the standard method, the slight erratic curves and the lack of specificity sometimes
observed (blue line in the class 2 instead of class 1) is due to the fact that this method generates
a low number of different best cut-off values (between 8 and 64) in the best cut-off distribu-
tions, as explained in the S1 Text. As summarized in S9 Table, these results confirm that the
probability system of classification is an efficient variant classifier. Indeed, whatever method is
used, when the pathogenic and neutral distributions are strictly identical, they all locate inside
the class 3 area (i.e., the system cannot classify any variants in such kind of functional assay).
Moreover, the probability system of classification is improved when the pathogenic mutations
shift from the neutral sector towards the pathogenic sector, since the probability of pathogenic-
ity increases for the pathogenic variants and decreases for the neutral ones.
(PDF)
S14 Fig. Effect of the position of the neutral mutations on the probability system of classifi-
cation (theoretical situation). See S13 Fig for details. Neutral mutations were shifted accord-
ing to the formula vij + 36 × s, with s representing the shift intensity and vij representing the
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value i of the neutral mutation j (when s = 0, medians and extreme values of the BRCA1 and
neutral distributions are identical. When s = 2, pathogenic and neutral distributions are identi-
cal). (A-D) Examples of shift intensities and best cut-off fluctuation results. The s values are
indicated (top left). (E) Probabilities of pathogenicity obtained for the neutral (blue line) and
pathogenic variants (red line), depending on the shift intensity of the neutral mutations. As
summarized in S9 Table, these results highlight divergences between the different methods.
With the standard method and the standard with reference methods (E, left and middle pan-
els), sensitivity and specificity of the probability system of classification decrease when the neu-
tral mutations approach the pathogenic mutations. With the MWWmethod (E, right panel),
the probability system of classification results in a complete misclassification of the pathogenic
mutations when the neutral distributions do not overlap the WT reference distribution (s 1).
Of note, these analyses treat extreme situations. In practice, the WT reference should be well
embedded within the neutral distributions. The opposite situation would raise question about
the WT reference or neutral mutations used.
(PDF)
S15 Fig. Effect of the position of the WT BRCA1 reference on the probability system of
classification (theoretical situation). See S13 Fig for details. Values of the WT BRCA1 distri-
bution were shifted according to the formula vi + 36 × s, with s representing the shift intensity
and vi representing the value i of the BRCA1 reference (when s = 0, medians and extreme val-
ues of the neutral and BRCA1 distributions are identical. When s = 2, medians and extreme
values of the pathogenic and BRCA1 distributions are identical). Of note, these theoretical
analyses treat extreme situations. In practice, the WT reference should be well embedded in the
neutral distributions. The opposite situation would raise question about the WT reference or
neutral mutations used. (A-D) Examples of shift intensities and best cut-off fluctuation results.
The s values are indicated (top left). (E) Probabilities of pathogenicity obtained for the neutral
(blue line) and pathogenic variants (red line), depending on the shift intensity of the WT refer-
ence. As summarized in S9 Table, these results highlight divergences between the different
methods. As expected, the standard method is not affected by the position of the WT BRCA1
distribution (E, left panel). In contrast, the standard with reference method is strongly influ-
enced by the position of this reference (E, middle panel). When the WT BRCA1 median shifts
towards the null value, sensitivity and specificity of the probability system of classification are
decreased, with a complete loss of sensitivity and specificity (i.e., systematic classification as
class 3) when the WT BRCA1 median is null (s -0.514). This was expected since the standard
with reference method is based on best cut-off values divided by the WT BRCA1 median.
Thus, a division by zero generates relative best cut-offs with an infinite value. Such issues are
compensated only when best cut-offs are close to the WT BRCA1 median. This was shown in
the Liquid Medium and Yeast Localization assays. Using the standard or standard with refer-
ence method provided similar variant classification (Fig 2B), even if the WT BRCA1 medians
of these assays approached zero, with 0.144 and 0.03 respectively (S4 Table). In conclusion, a
situation, in which the WT reference median is close to zero, with the fluctuation of the raw
best cut-off far from this median, will guarantee a weak sensitivity and specificity of the proba-
bility system of classification. Concerning the standard with reference method, it is also note-
worthy that a negative value of the WT reference median (s< -0.514) inverts the classification
(E, middle panel), as expected, regardless of the values from the neutral and pathogenic muta-
tions. When comparing the standard with reference method versus the MWWmethod, the
later has the advantage of being independent of the WT reference values, as only overlapping
distributions matter. Specificity of the probability system of classification is not affected by the
position of the WT reference, contrary to sensitivity (E, right panel). The main weakness of the
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MWWmethod occurs when the WT reference distribution falls outside of the range of the
neutral and pathogenic distributions (as in A, left panel), which generates misclassification of
the pathogenic mutations as neutral.
(PDF)
S16 Fig. Effect of the experimental sensitivity and specificity on the probability system of
classification (theoretical situation). See S13 Fig for details. The experimental sensitivity and
specificity were modulated by assigning certain pathogenic mutants in the neutral region and
certain neutral mutants in the pathogenic region, respectively. The experimental sensitivity
and specificity values indicated were those obtained with the experimental best cut-off, as
explained in S2 Fig. These values are referred to as "initial" sensitivity and specificity, as
opposed to the sensitivity and specificity of the probability system of classification, obtained
after bootstrap analysis. (A-D) Examples of experimental sensitivities/specificities and best
cut-off fluctuation results. (E-G) Probabilities of pathogenicity obtained for the neutral (blue
line) and pathogenic variants (red line), depending on decreases from experimental specificity
(E), experimental sensitivity (F) or both (G). As summarized in S9 Table, these results confirm
that the probability system of classification is an efficient variant classifier. A decrease of the
experimental specificity indicates that the pathogenic area is contaminated by neutral variants,
which reduces the probability of pathogenicity of the pathogenic variants (class 5 towards class
3). In the same manner, a decrease of the experimental sensitivity indicates that the neutral
area is contaminated by pathogenic variants, which enhances the probability of pathogenicity
of the neutral variants (class 1 towards class 3). This was observed using the three standard,
standard with reference and MWWmethods. Of note, the situations studied used systemati-
cally: experimental sensitivity + experimental specificity 1 (otherwise representing an inap-
propriate use of the experimental information, i.e., pathogenic and neutral sectors incorrectly
positioned).
(PDF)
S17 Fig. Effect of the number of neutral and pathogenic mutations on the probability sys-
tem of classification (theoretical situation). See S13 Fig for details. (A-D) Examples showing
the number of neutral and pathogenic mutations tested, with best cut-off fluctuation results.
(E-G) Probabilities of pathogenicity obtained for the neutral (blue line) and pathogenic vari-
ants (red line), following a decrease in the number of neutral mutations (E), pathogenic muta-
tions (F) or both (G). As summarized in S9 Table, these results show that the probability
system is poorly sensitive to the number of neutral and pathogenic mutations incorporated,
whatever method is used.
(PDF)
S18 Fig. Effect of the number of mutant and BRCA1 values on the probability system of
classification (theoretical situation). See S13 Fig for details. Number of values was modulated
so that the range and median of the distributions remained the same, as shown in S8 Table.
(A-D) Examples showing the number of mutant or BRCA1 values tested, with best cut-off fluc-
tuation results. (E-G) Probabilities of pathogenicity obtained for the neutral (blue line) and
pathogenic variants (red line), following a decrease in the number of mutant values (E),
BRCA1 values (F), or both (G). As summarized in S9 Table, these results confirm that the
probability system of classification is an efficient variant classifier. Whatever method is used, a
decreasing number of values in the dataset affects the probabilities of both the pathogenic and
neutral variants (G), which tend toward 0.5 (class 3). Thus, the probability system prevents
decision-making when data is lacking. As expected, the standard method is not affected by the
number of BRCA1 values (F, left panel). The standard with reference and the MWWmethods
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are insensitive to the number of mutant values if the number of BRCA1 values is high (E, mid-
dle and right panels). However, a decrease in the number of BRCA1 values lowers the probabil-
ity of pathogenicity of the pathogenic variants (F, middle and right panels), but with a strong
recovery when the fluctuation of the best cut-off is no longer influenced by the fluctuation of
the WT reference (nBRCA1 = 1). Of note, the best cut-off does not fluctuate when nmutant = 1
and nBRCA1 = 1 (G), which results in a probability of pathogenicity equal to 0.5 for both the
pathogenic and neutral variants. Moreover, using the standard method, when nmutant = 9, the
classification of the neutral mutations is class 2 (E, left panel), which explains the lack of speci-
ficity frequently observed in S13–S19 Figs.
(PDF)
S19 Fig. Effect of the range of mutant and BRCA1 distributions on the probability system
of classification (theoretical situation). See S13 Fig for details. Distribution ranges were mod-
ulated so that medians remained the same, as shown in S8 Table. The range factor r, indicated
on the graphs, illustrates the relative dispersion of the distributions. When r = 0, the dispersion
is null. (A-D) Examples showing the ranges of the mutant and BRCA1 distributions tested,
with best cut-off fluctuation results. (E-G) Probabilities of pathogenicity obtained for the neu-
tral (blue line) and pathogenic variants (red line), following a range decrease of the mutant dis-
tributions (E), BRCA1 distribution (F), or both (G). As summarized in S9 Table, these results
indicate that the probability system of classification is affected mainly when the range of the
BRCA1 and mutant distributions is null, whatever method is used. In this situation, the fluctu-
ation of the best cut-off is null and all the mutations are considered as absolutely unknown
(probability of pathogenicity equal to 0.5).
(PDF)
S20 Fig. Western blot analysis. After 4 hours of BRCA1 expression, lysates of 6 x 106 cells
were examined for the presence of the protein (theoretical size: 200 kDa) with an anti-BRCA1
antibody. Tubulin or Actin was used as a loading control and was probed using an anti-Tubu-
lin or anti-Actin antibody on the same membrane after stripping the first labeling. Signal inten-
sities of full lanes, relatively to the BRCA1 lane, are indicated below. Of note, protein levels
three times higher than the WT BRCA1 protein level (normalized to 1) systematically corre-
spond to pathogenic mutations. (A) BRCA1 (Colony Size and Liquid Medium assays). (B)
BRCA1-mCherry (Spot Formation and Yeast Localization assays). (C-G) Dotplot with the
Spearman coefficient of correlation indicated. Pathogenic and neutral mutations, as well as the
WT BRCA1 reference, are represented by a red, blue or black dot, respectively. (C) Correlation
between the relative signal intensities of A and B. (D-E) Correlation between the relative signal
intensities of A and medians of the Colony Size or Liquid Medium assay. (F-G), correlation
between the relative signal intensities of B and medians of the Spot Formation or Yeast Locali-
zation assay.
(PDF)
S21 Fig. Exact probability distribution of the best cut-off in the standard, standard with
reference and MWWmethods (theoretical situation). The theoretical situation was analyzed
as follows: one neutral and one pathogenic mutation (nneutral = 1 and npathogenic = 1), with two
values per mutant (nmutant = 2, value 1 and 2 for the neutral mutant, and value 3 and 4 for the
pathogenic mutant) and two values in the WT BRCA1 reference (nBRCA1 = 2, value 1 and 2).
(A) The graphs depicted are similar to those in Fig 1, except that boxplots are replaced by dot-
plots with median of the distributions indicated by a grey segment. The black horizontal line
represents the experimental best cut-off. The best cut fluctuations (colored areas) are not repre-
sented but quantiles are shown in F. (B) Table recapitulating all of the possible results when
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sampling 2 values, with replacement, among the 2 neutral, 2 pathogenic and 2WT BRCA1 val-
ues. Each row is a different combination that provides a best cut-off value, for each method
used. The framed row highlights the combination identical to the experimental situation in A.
In this simple situation (1 neutral and 1 pathogenic variant), the best cut off computed, in each
row, is the median of the two variant medians (standard method), the median of the two vari-
ant medians divided by the WT BRCA1 median (standard with reference method) and the
median of the two variant p values (MWWmethod). (C-E) Variant classification using the
probability system, with the standard (C), standard with reference (D) and MWW (E) meth-
ods, as in S6B Fig. Colored numbers in the table correspond to the different probabilities of
pathogenicity designed by the model. The color code respects the five-class nomenclature
depicted in S1 Table: grey, class 3; light blue, class 2; pink, class 4. Positions of the neutral and
pathogenic variants are represented by a blue and red arrow, respectively. The number below
each arrow designates the variant value used in the probability system to attribute the probabil-
ity of pathogenicity, which corresponds to the median, median divided by the WT reference
median or p value, indicated in the framed row of B. For instance, in the standard method (C),
the pathogenic variant, with a median of 3.5, has the probability 0.94 (class 3). (F) Variant clas-
sification using the quantile system. Quantiles were computed from the 27 best cut-off values
from B, for each method. The colored background defines the intervals within the best cut-off
distribution, as explained in S23 Fig. Arrows depict the position of the neutral and pathogenic
variants, as in C-E.
(PDF)
S22 Fig. Additional information about the classification model. (A) Schematic of the exact
best cut-off distribution influenced by different parameters, assuming no ties. The number of
neutral (nneutral) and pathogenic (npathogenic) variants influence the exact best cut-off distribu-
tion only if the number of values per mutant (nmutant) is above 1. The number of values in the
WT reference (nBRCA1) does not influence the exact best cut-off distribution in the standard
method, only in the standard with reference and MWWmethods. (B) Schematic of the approx-
imate best cut-off distribution influenced by the number of bootstraps performed. Importantly,
a single bootstrap (nbootstrap = 1) does not lead to the experimental best cut-off, except if nbest
exact = 1. (C) Accuracy of the probability and quantile systems of classification. The schematic
illustration is valid, using either the exact or approximate best cut-off distribution. (D) Correct-
ing factor fcor used in the probability system of classification, depending on the parameter a
(see the S1 Text). fcor = (nneutral + npathogenic) / (nneutral + npathogenic + a). The framed value
(a = 2) was the value used in S13–S15 Tables.
(PDF)
S23 Fig. Description of the quantile system of classification. (A) The left figure depicts a the-
oretical waterfall distribution of pathogenic and neutral missense mutations, as in Fig 1A. (1)
Variant classification according to the experimental best cut-off. This cut-off (horizontal black
line), that maximizes the experimental sensitivity and specificity in the waterfall distribution, is
obtained by ROC curve analysis, as in S2 Fig. In the case of the Colony Size assay, mutations
above the best cut-off are classified as pathogenic and mutations below are classified as neutral.
(2) Bootstrap analysis provides a fluctuation of the best cut-off, depending on the values of the
mutations and the WT BRCA1 reference randomly chosen. The fluctuating best cut-off values
form a distribution, as depicted in the schematic. (3) Quantile system of variant classification
according to the fluctuation of the best cut-off. The reasoning is the following: the distribution
of the fluctuating best cut-off defines quantiles (Q) that delimit the probability of the presence
of this variable. As an example, the quantile Q0.99 is the value that separates the 99% lowest
values from the 1% highest values in a distribution. This means that the probability to have the
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best cut-off above the quantile Q0.99 is 1%. Thus, in the Colony Size assay using the standard
method, a mutation with the median above the quantile Q0.99 can be considered as pathogenic
with a 1% probability of error. Indeed, this mutation could be neutral, but only if the best cut-
off is above the median, which has a 1% probability, or less, to occur. This reasoning allows sep-
aration of the best cut-off distribution into 5 intervals, based on the five-class nomenclature
proposed by Plon et al [26], with each interval defining the probability of the best cut-off pres-
ence within the waterfall distribution. (B) Quantiles that delimit the 5 intervals of classification
according to the assay and the method used. CS, Colony Size; LM, Liquid Medium; SF, Spot
Formation; YL, Yeast Localization assay. Note that the quantiles differ, depending on whether
the pathogenic mutations are above or below the best cut-off. For instance, in the standard
method, the quantiles of the Colony Size assay are Q0.99, Q0.95, Q0.05 and Q0.001 (patho-
genic mutants above the best cut-off), while quantiles are Q0.01, Q0.05, Q0.95 and Q0.999 in
the Spot Formation assay (pathogenic mutants below the best cut-off). However, these two
cases generate the same intervals (e.g., probability 1% for the class 5, see C andD). Cut-off val-
ues corresponding to these quantiles are listed in S5 Table for each assay and for each method.
(C) Interval limits in the case of the Colony Size assay, using the standard or the standard with
reference method. P(X> Q0.99) = 1% is the probability to obtain the best cut-off variable X
strictly over the quantile Q0.99, shown here as 26,222 cells per colony for the standard method,
and 2.416 x 11,200 (BRCA1 median of the experimental data) = 27,062 cells per colony for the
standard with reference method. (D) Interval limits in the case of the Colony Size assay, using
the MWWmethod.
(PDF)
S24 Fig. Variant classification using the quantile system. Names in red and in blue indicate
the pathogenic and neutral mutations, respectively, according to their prior classification. See
also S16 Table. The black frames pinpoint the divergent classification compared to that in the
probability system (Fig 2B).
(PDF)
S25 Fig. Quantile system of classification (theoretical situation). Effect of different experi-
mental parameters was assessed in theoretical situations, exactly as for the probability system
of classification, meaning that the best cut-off fluctuations depicted were those used in S13–
S19 Figs. Red line, position of the median or p value of the pathogenic mutants; blue line, posi-
tion of the median or p value of the neutral mutants. The pink, grey and blue areas define inter-
vals within the best cut-off distribution, as explained in S23 Fig. For clarity, the extreme red
and blue areas were not displayed. Sensitivity of the quantile system is maximal when the red
line is beyond the pink area. Specificity is maximal when the blue line is beyond the light blue
area. Accuracy is maximal when sensitivity and specificity are maximal. Finally, sensitivity,
specificity and accuracy of the quantile system are null when both lines are in the grey area, or
in the wrong side of the best cut-off fluctuation. (A-D) Evolution of the best cut-off fluctuation
depending on either the shift intensity of the pathogenic mutations (A), or the shift intensity of
the neutral mutations (B), or the shift intensity of the WT reference (C), or the experimental
sensitivity and specificity (D). The corresponding panels, depicted for the probability system of
classification, are shown in S13D Fig for A, S14E Fig for B, S15E Fig for C and S16E–S16G Fig
forD. As summarized in S17 Table, these results did not reveal any flaws. The quantile system
behaves as the probability system, in these situations.
(PDF)
S26 Fig. Quantile system of classification (theoretical situation). Evolution of the best cut-
off fluctuation depending on either the number of neutral and pathogenic mutations (A) or the
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number of mutant and BRCA1 values (B), as in S25 Fig. The corresponding panels, depicted
for the probability system of classification, are shown in S17E–S17G Fig for A and S18E–S18G
Fig for B. As summarized in S17 Table, these results reveal a major flaw in the quantile system
of classification. Using the standard and MWWmethods, the sensitivity and specificity is max-
imal, regardless of the number of values present within the mutant or BRCA1 distributions
(B). Using the standard with reference method, the sensitivity is affected when the number
of values in the BRCA1 distribution is decreased, but is maximal when nBRCA1 = 1. Thus, con-
trary to the probability system, the quantile system is not correctly influenced by the amount of
experimental values resulting from functional assessment.
(PDF)
S27 Fig. Quantile system of classification (theoretical situation). Evolution of the best cut-
off fluctuation, depending on the range of the mutant and BRCA1 distributions, as in S25 Fig.
The corresponding panels, depicted for the probability system of classification, are shown in
S19E–S19G Fig. As summarized in S17 Table, these results reveal a major flaw in the quantile
system of classification. A null range means that all of the values, present in a distribution, are
identical (ties). Because ties are related to a low measurement accuracy, an efficient variant
classifier should penalize a high number of ties in a dataset, which is not observed here, what-
ever method is used.
(PDF)
S1 Table. IARC variant classification. Five-class nomenclature proposed by the International
Agency for Research on Cancer (IARC) for variant classification, with specific recommenda-
tions for clinical management, depending on the probability of pathogenicity obtained by epi-
demiological methods [26].
(XLS)
S2 Table. BRCA1 mutations selected. a Empty cell, no data. b HGVS: human genome varia-
tion society (http://www.hgvs.org/mutnomen/). c IARC classification as in S1 Table. d UMD-
BRCA1 database (29-January-2015, http://www.umd.be/BRCA1/). e LOVD-IARC database
(29-January-2015, http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA1). f LOVD Lei-
den database (29-January-2015, http://databases.lovd.nl/shared/genes/BRCA1). This database
gathers all information from the literature, including functional assays, which explains the high
level of ambiguous results. Blue cell, neutral; red cell, pathogenic; grey cell, conflicting reports.
g Mutations recommended by the ENIGMA consortium. C64Y is namely classified as "Clini-
cally important" which is here converted to "4/5".
(XLS)
S3 Table. Misclassified mutations using the experimental best cut-offs. Experimental best
cut-offs from Table 1.
(XLS)
S4 Table. Experimental data from the 4 functional assays and the siRNA screening. Relative
median, median divided by the WT BRCA1 median or by the No siRNA median; sample size,
number of values; framed mutations indicate identical p values. The "ties" column indicates the
number of values repeated. For instance, in the first row, one value is repeated twice, another
one four times, and a third twice ("ties" is the statistical term used to designate "identical val-
ues").
(XLS)
S5 Table. Distribution of the best cut-offs after bootstrap analysis. Values obtained after
sampling, with replacement, using the original data obtained from the four functional assays
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and the siRNA screen (see the bootstrap procedure A in the method section). Q indicates the
quantile (Q0.050 is the quantile 5%). For the standard with reference method, the results
shown represent values either relative to the median of the WT reference (BRCA1 reference or
No siRNA), which allows an immediate comparison of the cut-off distributions between the
different assays (top), or the same values multiplied by the experimental median of the WT ref-
erence observed in the corresponding assay (bottom). For example, 0.960 is the quantile 0.1%
in the Colony Size assay, which corresponds to 11,200 x 0.960 = 10,754 cells per colony. Experi-
mental medians used are 11,200 cells per colony (Colony Size assay), 0.144 OD600 (Liquid
Medium assay), 32% (Spot Formation assay), 3% (Yeast Localization assay) and 945 (siRNA
screen), as indicated in S4 Table. Of note, in the standard method, the WT reference was
ignored during the sampling. Thus, the resulting fluctuation of the best cut-offs does not
depend on the fluctuation of the WT reference. This explains why distributions were narrowed
in the standard method, compared to the standard with reference method. For example, 12,133
cells per colony is the quantile 0.1% in the Colony Size assay, but in the standard with reference
method, the same quantile is slightly farther from the distribution median, with a value of
11,200 x 0.960 = 10,754 cells per colony.
(XLS)
S6 Table. Quantitative analysis of Fig 2B. "Balance" indicates the number of mutations cor-
rectly classified (class 1 + 2 + 4 + 5) minus the total number of mutations misclassified. "Sensi-
tivity" and "Specificity" represent the number of variants correctly classified, divided by the
number of variants in the prior classification (npathogenic = 25 and nneutral = 15). "Accuracy"
is the number of mutations correctly classified (class 1 + 2 + 4 + 5) divided by the total number
of mutations (n = 40).
(XLS)
S7 Table. Features of the assays. See S4 Table for details.
(XLS)
S8 Table. Examples of theoretical situations analyzed. The "reference situation" column indi-
cates the initial values and parameter settings. From this, distribution parameters were modified
and the resulting variant classification was scrutinized. The separating factor s (BRCA1, neutral
or pathogenic) shifts the values of the distribution, according to the formula vij + 36 × s, with vij
representing the value i of the distribution j (BRCA1, neutral or pathogenic). The range factor r
modulates the extreme values of a distribution, according to the formula me ± 17.5 × r, where
me represents the median of the distribution. Whatever the value of r, the values of any distribu-
tion are equally spread.
(XLS)
S9 Table. Effect of functional assay parameters upon the probability system of classifica-
tion. Sensitivity and specificity are defined here as the probabilities of pathogenicity (p) attrib-
uted to the pathogenic and neutral mutations, respectively, which reflects the accuracy of the
probability system of variant classification. Sensitivity is maximal if p 0.95 for the pathogenic
mutations. Specificity is maximal if p< 0.05 for the neutral mutations. Misclassification is
defined as p 0.95 for the neutral mutations and p< 0.05 for the pathogenic mutations. The
experimental sensitivity and specificity derives from the experimental best cut-off, as explained
in S2 Fig. They differ from the sensitivity and specificity described above, since they are related
to the initial position of the pathogenic and neutral mutants before random sampling. +++,
very influenced; 0, no effect.
(XLS)
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S10 Table. Plasmids used. a Mutation and deletion nomenclature according to the human
genome variation society (http://www.hgvs.org/mutnomen/). b The BRCA1 cDNA used in
Millot et.al [11], corresponds to the AY888184.1 GenBank sequence, slightly modified in this
study (see the Methods section).
(XLS)
S11 Table. Yeast strains used. a "mCherry" was omitted in the main text. For instance, the
P1859R-mCherry strain was referred to as "P1859R".
(XLS)
S12 Table. Average CDF of the probability system of classification when using the standard
method. See S6C Fig for details. The 272 middle values of the average CDF, derived from the
Colony Size assay, were removed to simplify the table. Colored numbers indicate the 5-class
nomenclature (S1 Table): dark blue, class 1; light blue, class 2; pink, class4; red, class 5. This
table was used to attribute the probabilities of pathogenicity depicted in Fig 2B. For instance, in
the Colony Size assay, the median of P1776H is 12,253 cells per colony. The closest best cut-off
value of this median belongs to rank 8, meaning that, when using the standard method, the
probability of pathogenicity attributed to P1776H is 0.00475. Of note, if a best cut-off value is
not repeated, among the 2,000 best cut-off values used to derive the CDF, then the associated
probability is 1 / 2,000 = 0.0005 for this value. This indicates the minimal probability incremen-
tation between two non repeated consecutive best cut-off values in the CDF (probability unit).
In the Yeast Localization assay, no variant can be classified as class 5 due to a lack of unre-
peated values at the "pathogenic" side of the best cut-off distribution (the highest cut-off value,
0.2151616, is present 97 times, leading to a probability of 0.0485 and an average cumulative
probability of 0.97550 in the CDF, which is inferior to the 0.99 probability threshold of the
class 5)).
(XLS)
S13 Table. Basic and corrected probability of pathogenicity when using the standard
method. See Fig 2B for details. Values in the "Probability" columns are those in Fig 2B. Muta-
tions are ordered as in Fig 2B to facilitate comparisons. Odds in favor of pathogenicity are the
ratio pi / (1—pi), with pi being the probability of pathogenicity of the variant i. The Liquid
Medium and Yeast Localization assays were not included in the combined odds, since the Liq-
uid Medium and Colony Size, as well as the Spot Formation and Yeast Localization, are not
independent assays. Combined probabilities of pathogenicity result from the ratio Oi / (1 + Oi),
with Oi being the combined odds of the variant i. Probabilities were also corrected according to
nneutral + npathogenic = 40 and a = 2 (see the S1 Text). CS, Colony Size assay; SF, Spot For-
mation assay.
(XLS)
S14 Table. Basic and corrected probability of pathogenicity when using the standard with
reference method. See S13 Table for details.
(XLS)
S15 Table. Basic and corrected probability of pathogenicity when using the MWWmethod.
See S13 Table for details.
(XLS)
S16 Table. Quantitative analysis of S24 Fig. Framed numbers highlight the differences with
the results obtained using the probability system of classification (S6 Table).
(XLS)
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S17 Table. Effect of functional assay parameters upon the quantile system of classification.
Sensitivity and specificity are defined here as the distance between the best cut-off fluctuation
and the position of the pathogenic and neutral mutations, respectively, which reflects the accu-
racy of the quantile system of variant classification. For instance, the MWWmethod exhibits a
null sensitivity in variant classification if the p values of the pathogenic mutations are in the
grey area (class 3), and shows a maximal sensitivity in variant classification if the p values are
in the pink area (class 4) or beyond (class 5). Misclassification is defined as class 4 or 5 for the
neutral mutations and class 2 or 1 for the pathogenic mutations. See S9 Table for further
details. The framed text indicates differences, as compared to the probability system of classifi-
cation (S9 Table)
(XLS)
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